Etidronic Acid

Etidronic Acid

SCHEMBL205727

CC(O)(P(=O)(O)O)P(=O)(O)O.[NaH]

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.93
FDPS P14324 15/20 0.47
PGK1 P00558 1/20 0.45
PGK2 P07205 1/20 0.45
CA2 P00918 1/20 0.38
GGPS1 O95749 7/20 0.35
ADRB3 P13945 1/20 0.33
PDE4D Q08499 1/20 0.33
PDE3A Q14432 1/20 0.33
THRB P10828 1/20 0.33
GRM4 Q14833 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Etidronic Acid SCHEMBL1527591 1.00 LMNA (0.93) LMNAFDPSPGK1PGK2CA2
Etidronic Acid SCHEMBL41737 1.00 LMNA (0.93) LMNAFDPSPGK1PGK2CA2
Etidronic Acid SCHEMBL94632 1.00 LMNA (0.93) LMNAFDPSPGK1PGK2CA2
Etidronic Acid SCHEMBL17961664 1.00 LMNA (0.93) LMNAFDPSPGK1PGK2CA2
Etidronic Acid SCHEMBL7764099 1.00 LMNA (0.93) LMNAFDPSPGK1PGK2CA2
Etidronic Acid SCHEMBL4595371 1.00 LMNA (0.93) LMNAFDPSPGK1PGK2CA2
Etidronic Acid SCHEMBL10957057 0.97 LMNA (0.87) LMNAFDPSPGK1PGK2CA2
Etidronic Acid SCHEMBL6850113 0.97 LMNA (0.87) LMNAFDPSPGK1PGK2CA2
Etidronic Acid SCHEMBL10705565 0.97 LMNA (0.87) LMNAFDPSPGK1PGK2CA2
Etidronic Acid SCHEMBL18607 0.96 LMNA (1.00) LMNAFDPSPGK1PGK2CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1034 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127699-A1 One Pot Process for Preparing 'Grit-Free' Solid Cleansing Compositions GALAXY SURFACTANTS LTD. (IN) 2025-04-24 US claimed
EP-4541340-A1 A ONE POT PROCESS FOR PREPARING 'GRIT-FREE' SOLID CLEANSING COMPOSITIONS Galaxy Surfactants Ltd. (IN) 2025-04-23 EP claimed
EP-3691450-B1 QUATERNARY AMMONIUM ETIDRONATES INNOVATIVE WATER CARE LLC (US) 2024-08-21 EP claimed
CN-118480030-A Cerebulin ligands and bifunctional compounds comprising same 阿尔维纳斯运营股份有限公司 2024-08-13 CN claimed
CN-118340897-A Composition for enhancing anti-tumor effect of heme response agent based on cell in-situ assembly and application 无锡市南京大学锡山应用生物技术研究所 2024-07-16 CN claimed
CN-118267481-A Construction and application of mRNA nano delivery system with environment adaptability and cooperative regulation 浙江大学 2024-07-02 CN claimed
CN-118141982-A Biodegradable and injectable adhesive bone cement for osteoporosis and preparation method and application thereof 华东理工大学 2024-06-07 CN claimed
US-11971510-B2 Gel dosimeter for measuring radiation dose RIKEN (JP) 2024-04-30 US claimed
US-11960038-B2 Radiation dosimetry gel and radiation dosimeter comprising same as material for measuring radiation dose RIKEN (JP) 2024-04-16 US claimed
CN-117500507-A Phosphorus derivatives as novel SOS1 inhibitors 拜耳公司 2024-02-02 CN claimed
US-20070154559-A1 Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof SAMYANG BIOPHARMACEUTICALS CORPORATION (KR) 2007-07-05 US claimed
EP-1696961-A1 NANOPARTICLE COMPOSITIONS OF WATER-SOLUBLE DRUGS FOR ORAL ADMINISTRATION AND PREPARATION METHODS THEREOF Samyang Corporation (KR) 2006-09-06 EP claimed
WO-2005061004-A1 NANOPARTICLE COMPOSITIONS OF WATER-SOLUBLE DRUGS FOR ORAL ADMINISTRATION AND PREPARATION METHODS THEREOF SAMYANG CORPORATION (KR) 2005-07-07 WO claimed
EP-1465606-A2 DOSAGE FORM WITH A CORE TABLET OF ACTIVE INGREDIENT SHEATHED IN A COMPRESSED ANNULAR BODY OF POWDER OR GRANULAR MATERIAL, AND PROCESS AND TOOLING FOR PRODUCING IT TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2004-10-13 EP claimed
US-20030206954-A1 Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it LERNER E ITZHAK (IL) 2003-11-06 US claimed
WO-2003057136-A2 DOSAGE FORM WITH A CORE TABLET OF ACTIVE INGREDIENT SHEATHED IN A COMPRESSED ANNULAR BODY OF POWDER OR GRANULAR MATERIAL, AND PROCESS AND TOOLING FOR PRODUCING IT TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-07-17 WO claimed
EP-0364559-B1 SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS SCRIPPS RESEARCH INST (US) 1995-09-20 EP claimed
EP-0364559-A4 SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS 1991-01-09 EP claimed
EP-0364559-A1 SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS. SCRIPPS CLINIC RES (US) 1990-04-25 EP claimed
WO-1989008658-A1 SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1989-09-21 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250127699-A1 One Pot Process for Preparing 'Grit-Free' Solid Cleansing Compositions DEGS1, SGMS1, LIPA LMNA 2325/4885FDPS 1809/4885PGK1 2050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.